Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when she expects the National Institute for Health and Care Excellence to conclude its appraisal of Evusheld.

On 10 August 2022, the Department referred Evusheld to the National Institute for Health and Care Excellence (NICE) to evaluate its clinical and cost effectiveness for preventing COVID-19. From 29 July to 12 August 2022, NICE consulted with provisional stakeholders on the suggested remit, draft scope and provisional stakeholder list of consultees and commentators.

NICE has begun its evaluation and currently expects to publish draft guidance in April 2023 with final guidance in May 2023. In discussion with the manufacturer AstraZeneca, NICE is expediting the appraisal process by bringing forward the deadline for the company’s evidence submission in order to issue guidance to the National Health Service as soon as possible.